EVX B2
Alternative Names: EVX-B2Latest Information Update: 07 Sep 2022
At a glance
- Originator Evaxion Biotech
- Developer Evaxion Biotech; UMass Chan Medical School
- Class Bacterial vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Research Gonorrhoea
Most Recent Events
- 06 Sep 2022 Early research in Gonorrhoea (Prevention) in Denmark ( (Evaxion Biotech pipeline, September 2022)
- 10 Sep 2020 Preclinical trials in Cystic fibrosis associated respiratory tract infections (Prevention) (associated with pseudomonal infections ) in Denmark, prior to September 2020 (Evaxion Biotech pipeline, September 2020))
- 10 Sep 2020 Preclinical trials in Pseudomonal infections (Prevention) in Denmark, prior to September 2020 (Evaxion Biotech pipeline, September 2020)